NEW YORK, Sept 8 (Reuters) - The No. 2 research executive at Genentech is leaving for a post in academia -- marking one of the highest-profile departures since the U.S. biotechnology company was acquired by Swiss drugmaker Roche Holding AG (ROG.VX).
NEW YORK, Sept 8 (Reuters) - The No. 2 research executive at Genentech is leaving for a post in academia -- marking one of the highest-profile departures since the U.S. biotechnology company was acquired by Swiss drugmaker Roche Holding AG (ROG.VX).